Acadia has announced the acquisition of a private US biotech, CerSci Therapeutics.
Acadia paid US$52.5 million upfront in a cash-and-stock deal— US$47.2 million of it in Acadia shares. CerSci shareholders will also be eligible for up to US$887 million more in payments, plus royalties, dependent on development, commercialization, and sales milestones being met.
CerSci’s lead, early-stage asset is ACP-044, a potential therapy for both acute post-surgical and chronic nerve pain, which is designed to interfere with multiple pain pathways without presenting an addiction risk. A Phase 1 trial is planned for H1 2021.
CerSci also has preclinical programs in migraine and painful diabetic neuropathy and discovery-stage programs in neurodegenerative disease and opioid use disorder.
https://ir.acadia-pharm.com/sec-filings
https://www.fiercebiotech.com/biotech/acadia-adds-pain-meds-to-pipeline-52-5m-cersci-buyout
https://xconomy.com/san-diego/2020/...s-cersci-potential-pain-meds-in-52-5m-buyout/
https://cersci.com/
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.81 |
Change
-0.150(1.16%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $12.90 | $12.70 | $239.4K | 18.70K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 132 | $12.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.81 | 132 | 4 |
View Market Depth
| Last trade - 10.12am 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |